Introduction {#s1}
============

Invasive mold diseases (IMDs) such as aspergillosis, and less commonly mucormycosis and fusariosis are a serious complication of myelosuppressive chemotherapy administered for hematological malignancies \[[@B1]-[@B3]\]. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) or remission-induction chemotherapy for acute myelogenous leukemia / myelodysplastic syndrome (AML/MDS) are at especially high risk, with 20-fold higher rates of aspergillosis compared to patients with underlying lymphoma or multiple myeloma \[[@B4]\]. Although diagnostic advances and new antifungal therapies have improved survival rates in patients with invasive aspergillosis \[[@B1]\], nearly one-third of patients still die with the infection, or have interruption of life-saving chemotherapy while the mold infection is being treated \[[@B1]\]. As a result, many hematologists routinely screen patients for incipient mold infection with the serum galactomannan test and high resolution computer tomography if the patient has fever, or administer mold-active antifungal prophylaxis for prolonged periods even though only a small proportion of patients (4-12%) may go on to develop a mold infection \[[@B5],[@B6]\].

Risk stratification for IMD is a logical first step for identifying which patients would most likely benefit from more intensive monitoring or antifungal prophylaxis \[[@B7],[@B8]\]. However, the development of an IMD risk prediction model in patients with hematological malignancies is complicated by the low overall disease prevalence, infrequently analyzed genetic risk factors related to host innate immunity, and dynamic clinical and environmental variables during their course of treatment \[[@B8],[@B9]\]. Nevertheless, we hypothesized that an objective risk score for hematology patients based on easily documented demographic and clinical risk factors could have clinical utility if it accurately discriminates populations at low versus higher risk for developing IMD.

As a first step towards this goal, we retrospectively analyzed 17 candidate epidemiological and clinical risk factors for IMD in 840 patients during 2005-2008 to develop an objective risk score for proven or probable IMD. We then prospectively evaluated the performance of this risk score in 855 patients from 2009-2012. We found that a weighted risk score for IMD accurately discriminated a cohort of hematology patients at low (

\< 1% incidence) versus higher (\> 5% incidence) risk for mold infection, irrespective of the underlying malignancy, transplant status, and use of mold-active antifungal prophylaxis.

Design and Methods {#s2}
==================

Ethics statement {#s2.1}
----------------

The study was conducted in accordance with the Declaration of Helsinki, following review by the S'Orsola-Malpighi-University of Bologna ethics committee (<http://www.aosp.bo.it/content/comitato-etico>). Full review was waived because of the non-interventional, observational nature of the study. As a standard protocol in our institute, all patients included in the study provided an informed consent the first day of hospitalization.

Study Population {#s2.2}
----------------

This study was performed at a single regional hematology center in Italy (Institute of Hematology and Clinical Oncology "Lorenzo e Ariosto Seràgnoli", University of Bologna) during two periods. In the first study period (March 2005-December 2008), consecutive hospital admissions of patients with hematological malignancies were retrospectively analyzed for infections and IMD risk factors to develop a multivariate risk model for IMD. During the second study period (January 2009-December 2012), the performance of the risk score was prospectively analyzed in patients with a risk score calculated at the time of hospital admission, which was not reported to the treating hematologist. For each patient hospitalization, only the first infection episode was included in the analysis. Patients with hospitalizations shorter than 6 days were excluded from the analysis.

We collected data on 17 candidate predictors for IMD, which had been previously reported in the literature as risk factors for IMD in patients with hematological malignancies ([Table 1](#pone-0075531-t001){ref-type="table"}). Additional data pertinent to each hospitalization and infection episode were collected from clinical records and registered on a standardized data collection form by the treating hematologist, while demographic data were extracted from an institutional centralized database. The accuracy of collected data was confirmed by a quality control procedure during data entry and with periodic reviews by 4 physicians (2 hematologists, 1 infectious diseases specialist, and 1 radiologist).

10.1371/journal.pone.0075531.t001

###### Screened Risk Factors for Invasive Mold Disease.

  **Variable**   **Risk Factor**                                                                          **Definitions, comments**                                                                                                                                                                             **References**
  -------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------
  1              Age \> 40                                                                                Related to hematologic malignancy treatment response                                                                                                                                                  \[[@B20],[@B21]\]
  2              Profession with likely repeated exposure to fungal spores                                Patient works as a farmer, mason, carpenter/construction or has outdoor work with likely spore exposures                                                                                              \[[@B8]\]
  3              Smoking habits                                                                           Current user of tobacco or marijuana                                                                                                                                                                  \[[@B22]\]
  4              Prior clinical history of proven or probable mold disease                                Documented within 1 year of hospital admission                                                                                                                                                        \[[@B23]-[@B26]\]
  5              History of diabetes                                                                      Diagnosis of insulin-dependent or non-insulin-dependent diabetes mellitus                                                                                                                             \[[@B27]\]
  6              High-dose corticosteroid treatment                                                       0.5 mg/kg daily within 30 days prior to hospital admission                                                                                                                                            \[[@B25],[@B28]-[@B32]\]
  7              High-risk underlying malignancy                                                          Diagnosis of acute myeloid leukemia/ myelodysplastic syndrome, or aplastic anemia                                                                                                                     \[[@B4],[@B33]\]
  8              Malignancy status at time of admission                                                   Underlying malignancy is not in partial or complete remission.                                                                                                                                        \[[@B4],[@B21],[@B34]\]
  9              Hospital admission for high-risk chemotherapy                                            Patient currently receiving or admitted for chemotherapy to treat acute myeloid leukemia/ myelodysplastic syndrome, severe aplastic anemia, or for allogeneic HSCT conditioning chemotherapy          \[[@B4],[@B33],[@B35],[@B36]\]
  10             Prolonged neutropenia                                                                    Absolute neutrophil count \< 500 cells/µL for greater than 10 days within 30 days prior to admission or following chemotherapy                                                                        \[[@B7],[@B33],[@B37],[@B38]\]
  11             Lymphocytopenia or probable impaired lymphocyte function at time of admission            Lymphocytopenia (or probable impaired lymphocyte function) defined as an CD4^+^ count \< 50 cells/µL; or any allogeneic HSCT patient receiving cyclosporine, tacrolimus, or anti-thymocyte globulin   \[[@B25],[@B39],[@B40]\]
  12             Severe acute graft versus host disease after transplantation                             "Severe" graded according to Glucksberg \[[@B41]\] criteria                                                                                                                                           \[[@B42]\]
  13             Severe chronic graft versus host disease at admission                                    "Severe" graded according to Shulman \[[@B43]\] criteria                                                                                                                                              \[[@B25],[@B39]\]
  14             Severe mucositis during hospitalization                                                  WHO classification of Grade 3 or 4                                                                                                                                                                    \[[@B44]\]
  15             Cytomegalovirus infection                                                                Patient has evidence of active CMV infection diagnosed by pp65 antigen or quantitative PCR                                                                                                            \[[@B40],[@B45]\]
  16             Admission to a hospital room without high-efficiency particulate air (HEPA) filtration   Room does not contain central HEPA air filtration                                                                                                                                                     \[[@B46],[@B47]\]
  17             Admission to hospital room in proximity of construction                                  Patient was admitted to hospital room in a ward or building with ongoing construction                                                                                                                 \[[@B46],[@B48],[@B49]\]

Study endpoint {#s2.3}
--------------

The primary endpoint used for score development was documentation of proven or probable IMD within 90 days of hospitalization. Possible, probable or proven invasive aspergillosis (IA) and invasive mold disease (IMD) was defined according to the revised Mycoses Study Group and European Organization and Treatment of Cancer consensus criteria \[[@B10]\]. Serum galactomannan testing was routinely available at our institute after January 2007. Before this period, typical radiographic criteria as described by Cornely et al., were used to classify patients with proven or probable invasive aspergillosis \[[@B11]\]. In the case of non-*Aspergillus* molds not detected by galactomannan screening, diagnosis was always confirmed by histology or culture. Fluconazole (400 mg daily) was routinely administered to all patients undergoing allogeneic HSCT. Decisions regarding anti-mold antifungal prophylaxis in either non-transplant or transplant patients were at the discretion of the physicians caring for the patient.

Statistical Analysis {#s2.4}
--------------------

Demographic data were collected as either continuous data and compared by two-tailed unpaired *t*-test or Mann-Whitney test, or as categorical variables and compared by Chi-square test for patients with or without a probable or proven IMD. Variables with more than 5% missing data were excluded from analysis. Significant variables (*P*\<0.05) were entered stepwise in a multivariate logistic regression model to evaluate the relationship between each variable and IMD risk using the Wald's statistic. Variables that maintained statistical significance by multivariate regression were then assigned a point value corresponding to the β-coefficient of that variable divided by the lowest β-coefficient of variables remaining in the regression model, and the resulting quotient was multiplied by two and rounded to the nearest whole number. Summation of the points resulted in a weighted risk score that was assigned to each patient episode retrospectively (2005-2008), or prospectively (2009-2012) at the time of hospital admission.

The relationship of the calculated risk score and IMD risk was subsequently analyzed by receiver operator curves (ROC) to define an optimal cut-off score that discriminated low, versus high-risk patients. Our provisional cut-off was a risk score associated with 5% incidence of IMD, which has been proposed as the lower incidence limit of *Aspergillus* infection justifiable for antifungal prophylaxis in hematology patients \[[@B12]\]. All statistical analysis was performed using SPSS version 20 (IBM, Armonk, NY) and MedCalc 12.5 (Ostend, Belgium).

Results {#s3}
=======

Study populations {#s3.1}
-----------------

During the retrospective study period (2005-2008), we analyzed 1,709 hospital admissions from 840 patients with hematological malignancies. Each patient contributed a median of 2 separate hospitalizations to the database (range 1-12). The most common underlying malignancies were AML/MDS (31%), lymphoma (29%), and multiple myeloma/amyloidosis (25%) of which 63% were in partial or complete remission. Nearly 40% of the hospitalizations were for chemotherapy alone (i.e. no evidence of fever or infection on admission) with 46% of these admissions proceeding to HSCT (34% autologous, 12% allogeneic). Characteristics of the 1,709 cases are summarized in [Table 2](#pone-0075531-t002){ref-type="table"}.

10.1371/journal.pone.0075531.t002

###### Patient Demographic Characteristics.

  **Characteristic**                                                                      **2005-2008 Cohort;n=1,709 episodes(%**)   **2009-2012 Cohort;n=1,746 episodes(%**)   ***P* value^[a](#ngtab2.1){ref-type="table-fn"}^**
  --------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------ ----------------------------------------------------
  Median age (range)                                                                      52 (15-84)                                 52 (15-87)                                 0.92
  Sex, male                                                                               1,013 (59)                                 1,047 (60)                                 0.95
  Median no. of hospitalizations (range)                                                  2 (1-12)                                   1 (1-10)                                   0.52
  **Underlying malignancy**                                                                                                                                                     
  Acute myeloid leukemia/myelodysplastic syndrome                                         527 (31)                                   541 (31)                                   0.95
  Acute lymphoblastic leukemia                                                            176 (10)                                   193 (11)                                   0.51
  Chronic myelogenous leukemia                                                            50 (3)                                     6 (0.3)                                    \< 0.001
  Chronic lymphocytic leukemia                                                            19 (1)                                     65 (4)                                     \< 0.001
  Lymphoma                                                                                490 (29)                                   568 (36)                                   0.02
  Multiple myeloma/ amyloidosis                                                           418 (24)                                   332 (14)                                   0.001
  Aplastic anemia                                                                         13 (0.8)                                   18 (19)                                    0.51
  Non-neoplastic hematological disease                                                    16 (0.9)                                   23 (1)                                     0.37
  **Disease status**                                                                                                                                                            
  Newly diagnosed                                                                         197 (12)                                   192 (11)                                   0.67
  Complete/ partial response                                                              1030 (60)                                  1021 (58)                                  0.29
  Progression/ resistance/ relapse                                                        482 (28)                                   533 (31)                                   0.14
  **Type of treatment (%)**                                                                                                                                                     
  Induction chemotherapy                                                                  151 (9)                                    335 (19)                                   \< 0.001
  Other chemotherapy ^[b](#ngtab2.2){ref-type="table-fn"}^                                229 (13)                                   415 (24)                                   \< 0.001
  Rescue chemotherapy ^[c](#ngtab2.3){ref-type="table-fn"}^                               278 (16)                                   204 (12)                                   0.43
  Allogeneic HSCT                                                                         203 (12)                                   227 (13)                                   0.34
  Autologous HSCT                                                                         584 (34)                                   334 (20)                                   \< 0.001
  No chemotherapy ^[d](#ngtab2.4){ref-type="table-fn"}^                                   264 (15)                                   206 (12)                                   0.002
  Anti-mold prophylaxis^[e](#ngtab2.5){ref-type="table-fn"}^(systemically-active agent)   188 (11)                                   354 (20)                                   \< 0.001
  Empiric mold-active antifungal within 60 days of hospitalization                        239 (14)                                   148 (8)                                    \<0.0001

Pearson Chi-square for nominal data, Mann-Whitney or 2-tailed Students t-test for continuous data

Includes maintenance chemotherapy, consolidation chemotherapy

Chemotherapy administered for relapsed disease

Includes all admissions where chemotherapy was not administered (diagnostic, stem-cell mobilization, medical complications, etc.)

Prescribed agents: 2005-2008: itraconazole 10%, voriconazole 0.4%, lipid amphotericin B 0.6%; Prescribed agents 2009-2012: posaconazole 11.4%, itraconazole 8%, voriconazole 0.6%, lipid amphotericin B 0.3%

During the prospective score validation study period (2009-2012), we analyzed 1,746 hospital admissions in 855 hematology patients. Each patient contributed a median of 1 hospitalization episode (range 1-10) to the database. The breakdown of underlying malignancies in the prospectively studied cohort was similar to the retrospective cohort. However, significantly fewer patients in 2009-2012 were admitted with chronic myelogenous leukemia (0.3% vs. 3%, *P*\<0.001) or multiple myeloma/amyloidosis (14% vs. 24% *P*=0.001). Admissions associated with chronic lymphocytic leukemia (4% vs. 1%, *P*\<0.001) and lymphoma (36% vs. 29% *P*=0.02) were slightly higher during 2009-2012. Additionally, a higher proportion of hospital admissions in prospectively studied patients were for induction (19% vs. 9%, *P*\<0.001) or maintenance/ salvage chemotherapy (24% vs. 13%, *P*\<0.001); reflecting the activation of new protocols in our institute during 2009-2012. Fewer patients in 2009-2012 received an autologous HSCT (20% vs. 34%, *P*\<0.001), although rates of allogeneic HSCT were similar between the two study periods (13% vs. 12%, *P*=0.34).

Anti-mold antifungal prophylaxis was used more frequently in 2009-2012 (20% vs. 11%, *P*\<0.001), which was largely attributed to the introduction use of posaconazole after 2009 ([Table 2](#pone-0075531-t002){ref-type="table"}). The increased use of anti-mold prophylaxis was associated with a corresponding decrease in empirical antifungal therapy for molds (8% vs. 14%, *P*\<0.001). The most common anti-mold antifungal prophylaxis used during 2005-2008 was itraconazole capsules or solution (10%), which was largely replaced by posaconazole during 2009-2012 (11.4%) with some continued itraconazole use (8%). Voriconazole, lipid amphotericin B formulations, or aerosolized amphotericin B formulations were infrequently administered as prophylaxis during either study period (all less than 1%).

Risk Factors Associated with Proven or Probable IMD {#s3.2}
---------------------------------------------------

Among the 17 candidate variables evaluated in the retrospective cohort, 11 were associated with IMD by univariate analysis ([Table 3](#pone-0075531-t003){ref-type="table"}). These included patient occupational risk factors, the status of the underlying hematologic malignancy, variables related to the severity of underlying immunosuppression, a prior history of IMD, as well as the admission to a non-HEPA air-filtered room. However, in multivariate regression, only 4 of the 11 variables were independently associated with IMD risk: 1) Prolonged neutropenia, 2) lymphocytopenia or functional lymphocytopenia in allogeneic HSCT patients; 3) prior history of IMD, and 4) underlying malignancy that was not in partial or complete remission ([Table 4](#pone-0075531-t004){ref-type="table"}).

10.1371/journal.pone.0075531.t003

###### Univariate analysis of risk factors for invasive mold disease.

                                      **2005-2008 Cohortn=1,709 episodes**   **2009-2012 Cohortn=1,746 episodes**                                    
  ----------------------------------- -------------------------------------- -------------------------------------- --------- ------------ --------- ----------
  1-Age \>40                          1264 (77)                              44 (75)                                0.73      1,269 (75)   37 (67)   0.13
  2-At-risk profession                168 (10)                               10 (17)                                0.05      137 (8)      6 (11)    0.29
  3-Smoker                            542 (33)                               20 (34)                                0.65      419 (25)     13 (24)   0.50
  4-Prior IMD                         31 (2)                                 7 (12)                                 \<0.001   42 (2)       11 (20)   \< 0.001
  5-Diabetic                          156 (9)                                10 (17)                                0.03      105 (6)      3 (5)     0.55
  6-Corticosteroids                   312 (19)                               16 (27)                                0.06      192 (11)     12 (22)   0.02
  7-High-risk malignancy              555 (34)                               37 (63)                                \<0.001   552 (32)     29 (53)   0.006
  8-Uncontrolled malignancy           755 (46)                               47 (80)                                \<0.001   693 (41)     32 (58)   0.008
  9-High-risk chemotherapy            512 (31)                               37 (63)                                \<0.001   420 (25)     36 (65)   \<0.001
  10-Neutropenia \> 10 days           596 (36)                               48 (81)                                \<0.001   593 (35)     47 (85)   \<0.001
  11-Lymphocytopenia or dysfunction   415 (25)                               31 (53)                                \<0.001   222 (13)     35 (64)   \<0.001
  12-Acute GVHD, grade II-IV          47 (3)                                 5 (8)                                  0.02      35 (2)       5 (9)     \<0.001
  13-Chronic GVHD, extensive          28 (2)                                 1 (2)                                  0.07      9 (0.5)      1 (2)     0.36
  14-Mucositis, Grade III-IV          206 (12)                               14 (24)                                0.004     117 (7)      11 (20)   0.002
  15-CMV Infection                    62 (4)                                 4 (7)                                  0.18      48 (3)       5 (9)     0.02
  16-Admission to non HEPA room       587 (36)                               29 (49)                                0.01      482 (29)     21 (38)   0.45
  17-Proximity to construction        202 (12)                               8 (14)                                 0.64      412 (24)     10 (18)   0.19

See [Table 1](#pone-0075531-t001){ref-type="table"} for definitions

Chi square test

10.1371/journal.pone.0075531.t004

###### Multivariate regression model developed from the retrospective cohort of 1,709 hospitalizations (2005-2008).

  **Variable**                                **Frequency in patients with IMD (%)**   **β-coeff**   **Wald χ^2^**   ***P* value**   **Hazard Ratio(95% CI)**   **Points**
  ------------------------------------------- ---------------------------------------- ------------- --------------- --------------- -------------------------- ------------
  Duration of neutropenia                     596 (41)                                 1.72          21.99           \< 0.001        5.60 (2.72-11.50)          4
  Previous IMD                                31 (9)                                   1.71          12.42           \< 0.001        5.55 (2.14-14.41)          4
  Malignancy status                           755 (50)                                 1.53          19.46           \< 0.001        4.64 (2.34-9.19)           3
  Lymphocytopenia or lymphocyte dysfunction   415 (31)                                 0.90          9.57            0.002           2.45 (1.39-4.34)           2

Points assigned on the basis of the weighted odds ratios for these 4 independent variables resulted in a risk score from 0-13 for each patient (mean 3.3, 95% CI 3.1-3.4) ([Table 4](#pone-0075531-t004){ref-type="table"}). Risk scores were well calibrated with observed rates of IMD ([Figure 1](#pone-0075531-g001){ref-type="fig"}). When risk scores and the rates of true-positive and false-positive IMD rates were analyzed by ROC curves ([Figure 2](#pone-0075531-g002){ref-type="fig"}), a score of less than 6 was found to be optimal cut-off for discriminating low-risk patients with an area under the ROC curve (aROC) of 0.84 (0.79-0.89), sensitivity 0.86 (0.77-0.95), specificity 0.74 (0.73-0.75), positive predictive value (PPV) 0.10 (0.07-0.13), and negative predictive value (NPV) of 0.99 (0.99-1).

![Distribution of risk scores versus the cumulative incidence of proven or probable invasive mold disease.](pone.0075531.g001){#pone-0075531-g001}

![Analysis of risk score discrimination and optimal cut-off for invasive model disease risk.\
(a) Receiver-operator curve (ROC) analysis plot of the true positives plotted as a function of the false-positives (100-specificity) at different cutoffs of the risk score. Gray bands represent the 95% CI of the plot. The dotted line represents a reference line no discrimination for invasive mold disease (aROC=0.5). The *P* value is the probability that the aROC differs significantly from aROC=0.5; (b) Plot of sensitivity and specificity versus risk score. The highest sensitivity (true positive rate) and specificity (true negative rate) meet at a score just below 6, suggesting a criterion value of \> 6.](pone.0075531.g002){#pone-0075531-g002}

The IMD risk score derived from multivariate analysis of the 2005-2008 cohort was calculated for each patient at the time of hospital admission during 2009-2012, and patients were monitored for the development of probable or proven IMD within 90 days or hospital discharge. The mean risk score in 2009-2012 (mean 3.1, 95% CI 3.0-3.3) did not differ significantly from patients analyzed from 2005-2008. Similar to the retrospective cohort, risk scores for patients studied during 2009-2012 were well calibrated with the incidence rate of IMD within 90 days of hospital admission ([Figure 1](#pone-0075531-g001){ref-type="fig"}). A score of less than 6 was also confirmed as the optimal cut-off for discriminating low-risk patients in the prospective study cohort, with an aROC of 0.84 (0.82-0.86), sensitivity of 0.80 (0.67-0.89), specificity 0.76 (0.74-0.78), PPV 0.10 (0.07-0.13) and NPV 0.99 (0.99-1.0). When the risk score performance was analyzed in different subgroups of hematological malignancy patients with varying IMD prevalence (1.5% to 10.6%) and rates of anti-mold prophylaxis use (7.2% to 57%), we found that a score of \< 6 consistently identified a cohort of patients at low risk for IMD with NPVs ranging from 0.96-0.99 ([Table 5](#pone-0075531-t005){ref-type="table"}).

10.1371/journal.pone.0075531.t005

###### Predictive performance of the risk score in the 2009-2012 validation cohort.

  **Group**                                                                                      **Median risk score**   **Anti-mold prophylaxis during episode**   **IMD prevalence**   **aROC(95% CI)**   **Sensitivity(95% CI)**   **Specificity(95% CI)**   **Positive predictive value (95% CI)**   **Negative predictive value (95% CI)**
  ---------------------------------------------------------------------------------------------- ----------------------- ------------------------------------------ -------------------- ------------------ ------------------------- ------------------------- ---------------------------------------- ----------------------------------------
  All patientsn=1,746                                                                            3                       20%                                        3.2%                 0.84 (0.82-0.86)   0.80 (0.67-0.89)          0.76 (0.74-0.78)          0.10 (0.07-0.13)                         0.99 (0.99-1.0)
  Acute myeloid leukemia(remission-induction), n=131^[*a*](#ngtab5.1){ref-type="table-fn"}^      7                       57%                                        6.1%                 0.64 (0.55-0.72)   0.88 (0.47-0.99)          0.24 (0.17-0.33)          0.07 (0.03-0.14)                         0.97 (0.83-0.99)
  Acute myeloid leukemia (consolidation/salvage), n=284^[*b*](#ngtab5.2){ref-type="table-fn"}^   4                       46%                                        1.4%                 0.80 (0.75-0.85)   0.75 (0.19-0.99)          0.71 (0.65-0.76)          0.04 (0.007-.10)                         0.99 (0.97-1.0)
  Lymphoma, n=390^[b](#ngtab5.2){ref-type="table-fn"}^                                           3                       7.2%                                       1.5%                 0.99 (0.97-1.0)    1.0 (0.54-1.0)            0.94 (0.91-0.96)          0.20 (0.08-0.39)                         0.99 (0.99-1.0)
  Allogeneic HSCT, n=227                                                                         5                       13%                                        10.6%                0.72 (0.65-0.77)   0.88 (0.68-0.97)          0.33 (0.26-0.39)          0.13 (0.8-0.20)                          0.96 (0.88-0.99)

Only first admission for remission-induction chemotherapy was considered

Excludes patients who received allogeneic or autologous HSCT

Note: Risk score performance for autologous HSCT is not shown in the table because only 1 case of IMD was documented in 344 admissions

Impact of Posaconazole Prophylaxis {#s3.3}
----------------------------------

Posaconazole prophylaxis reduces the incidence of IMD in high-risk hematology patients and was associated with a mortality benefit in AML/MDS patients receiving remission- induction chemotherapy \[[@B13],[@B14]\]. We examined rates of proven or probable IMD among patients who had received posaconazole with risk scores of \< 6 versus \> 6 ([Figure 3a](#pone-0075531-g003){ref-type="fig"}). Posaconazole prophylaxis was not associated with any discernable benefit in terms of reducing the incidence of IMD in patients with risk scores of \< 6. However, among higher-risk patients with scores \> 6, posaconazole prophylaxis was associated with a 7.8% risk reduction in IMD (*P*=0.01). We also found that among 131 individual patients with AML/MDS undergoing remission-induction chemotherapy during 2009-2012, patients who received posaconazole prophylaxis had a significantly lower risk of crude mortality within 6 weeks of hospitalization \[[@B15]\], versus patients who did not receive posaconazole ([Figure 3b](#pone-0075531-g003){ref-type="fig"}) (HR 0.43, 0.2-0.9, *P*=0.04). This mortality difference was evident despite identical median risk scores (7) in patients who received and did not receive posaconazole prophylaxis.

![Impact of posaconazole prophylaxis on the incidence and mortality of invasive mold disease in the 2009-2012 validation cohort.\
(a) Cumulative incidence of invasive mold disease in patients with calculated risk scores \<6 or \> 6. *P* value determined by Chi-square test. (b) Kaplan-Meier analysis of crude mortality in patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing remission-induction chemotherapy by status of posaconazole prophylaxis. Each patient is analyzed only once and was classified as alive or dead at the time of discharge (censored) or death by day +42 after admission. *P* value was determined by the Mantel-Cox (log-rank) test.](pone.0075531.g003){#pone-0075531-g003}

Discussion {#s4}
==========

Physicians must weigh multiple factors when considering a patient's risk for developing IMD \[[@B16],[@B17]\]. Prognostic models or risk scores can complement this clinical assessment by providing an objective summation of multiple risk factors, thereby clarifying which patients should be targeted for more aggressive intervention \[[@B18]\]. To our knowledge, our single-institution study represents the first attempt to develop and validate an unconditional risk model for IMD in a heterogeneous population of patients with hematological malignancies. Our data demonstrate that an objective weighted risk score could reliably discriminate patients who had a very low probability of developing IMD within 90 days of hospitalization, and thus may be candidates for more conservative management with respect to higher-risk patients.

An ideal risk score for IMD in patients would have both a high negative predictive value (NPV) and high positive predictive value (PPV). Yet, development of such a risk score that could be applied for routine screening of a heterogeneous population of hematology patients is challenging, given the overall low prevalence of IMD and fluctuating risk factors for infection \[[@B8]\]. Alternatively, a risk score could be developed in a more homogenous high-risk population of with a higher prevalence of IMD (

\> 5%), such as allogeneic HSCT or AML/MDS patients undergoing remission-induction chemotherapy. Risk scores targeting populations who have already been shown to have proven to benefit from antifungal prophylaxis or intensive monitoring, however, may have less clinical utility for routine patient care \[[@B18]\] or considered too restrictive by treating physicians \[19\].

A limitation of our study is that our risk score was devised from observational data in a single center, and could not control for "real life" confounding factors such as use of antifungal prophylaxis. Notably, the discriminative performance of the risk score in our institution was similar among various subgroups of hematology malignancy patients with varying risk for IMD and usage patterns of antifungal prophylaxis. However, the performance of our risk score will undoubtedly vary in other hospitals depending on the type of patients treated and the baseline incidence of IMD. Additionally, clinical risk factors for IMD such as graft versus host disease and corticosteroids, which were not retained in our final risk model, would likely be more important if the score was developed specifically in allogeneic HSCT patients. Therefore multicenter validation and center-specific adjustments would likely be required if the risk score was applied to the clinical management of IMD in other hospitals.

In conclusion, we found than an objective, weighted risk-score for IMD could reliably discriminate the large majority of patients with hematological malignancies who were at low-risk for developing IMD. The discriminative performance of the score was consistent across various hematology patient subtypes with varying underlying baseline risk for IMD and exposure to antifungal prophylaxis. The continued refinement and multicenter validation of IMD risk scores could complement the clinical assessment of patients with hematological malignancies, and possibly improve the targeted use of diagnostics and antifungals in this immunocompromised population.
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